Brief: Rua Bioscience Says Shareholders Approve Zalm Therapeutics Share Issue
Jan 19 (Reuters) - Rua Bioscience Ltd RUA.NZ :
* SHAREHOLDERS APPROVE ZALM THERAPEUTICS SHARE ISSUE
* PURCHASE WILL BE UNDERTAKEN THROUGH ISSUE 28.7 MILLION
SHARES
OVER 3 YEARS TO ZALM THERAPEUTICS SHAREHOLDERS
* SHAREHOLDERS VOTED IN FAVOUR OF RUA ACQUIRING ZALM
THERAPEUTICS
* RUA EXPECTS TO FURTHER EXPAND PRODUCT OFFERING FOR
DOMESTIC &
GLOBAL MARKETS IN H2 OF 2022
Further company coverage: RUA.NZ
Recent news on Rua Bioscience
See all newsBrief: Rua Bioscience Partners With Curaleaf Laboratories For UK Distribution
Brief: Rua Bioscience Partners To Supply Medicinal MDMA In New Zealand
Brief: Pharmala Biotech Holdings Rua Bioscience And Pharmala Biotech Partner To Supply Medicinal Mdma In New Zealand
Brief: Rua Bioscience Posts Preliminary Unaudited Annual Results
New Zealand's Rua Bioscience FY customer revenue jumps on Australia, NZ growth